BIOMAT Database Logo BIOMAT Database Logo

Isolation and characterization of the fibrin intermediate arising from cleavage of one fibrinopeptide A from fibrinogen. 1996

J R Shainoff, and G B Smejkal, and P M DiBello, and O V Mitkevich, and P J Levy, and C E Dempfle, and H Lill
Department of Cell Biology, Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

The thrombin-catalyzed cleavage of N-terminal fibrinopeptide A (FPA) from the two Aalpha-chains of fibrinogen exposes aggregation sites with the critical sequence GPR located just behind FPA. It is well known that exposure of both GPR sites transforms fibrinogen into self-aggregating, fully coagulable alpha-fibrin monomers, but the fibrin precursor with one site exposed and one FPA intact has eluded description. The formation of this "alpha-profibrin" in the course of thrombin reactions and its distribution among both the aggregating and non-aggregating components of the reactions are characterized here by immunoprobing electrophoretic and gel chromatographic separations using monoclonal antibodies specific for FPA and for exposed GPR sites. These analyses show alpha-profibrin to be a non-aggregating derivative indistinguishable from fibrinogen in solutions that are rich in fibrinogen relative to dissolved fibrin. But alpha-profibrin forms soluble complexes with alpha-fibrin monomer under conditions in which it and fibrin predominate over fibrinogen. It was isolated as a complex with fibrin by gel chromatography of cryoprecipitates and then separated from the fibrin either by electrophoretic gel shifts induced with a peptide analog of the GPR aggregation site or by chromatographic gel shifts induced with monoclonal anti-FPA antibody. The weak aggregation of alpha-profibrin with itself and with fibrinogen conforms with prior indications that coupled interactions through the paired GPR sites on fibrin monomers are pivotal to their aggregation. It is suggested that alpha-profibrin may be a hypercoagulable fibrin precursor because it is converted to alpha-fibrin monomer faster than fibrinogen converts to monomer.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004587 Electrophoresis, Agar Gel Electrophoresis in which agar or agarose gel is used as the diffusion medium. Electrophoresis, Agarose Gel,Agar Gel Electrophoresis,Agarose Gel Electrophoresis,Gel Electrophoresis, Agar,Gel Electrophoresis, Agarose
D005337 Fibrin A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot. Antithrombin I
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D005344 Fibrinopeptide A Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin. Fibrinopeptides A
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

J R Shainoff, and G B Smejkal, and P M DiBello, and O V Mitkevich, and P J Levy, and C E Dempfle, and H Lill
Fibrinogen, fibrinopeptide A and fibrin monomers.
January 1977, Acta clinica Belgica,
J R Shainoff, and G B Smejkal, and P M DiBello, and O V Mitkevich, and P J Levy, and C E Dempfle, and H Lill
Substitution of tyrosine for phenylalanine in fibrinopeptide A results in preferential thrombin cleavage of fibrinopeptide B from fibrinogen.
September 1998, Biochemistry,
J R Shainoff, and G B Smejkal, and P M DiBello, and O V Mitkevich, and P J Levy, and C E Dempfle, and H Lill
Cell proliferation on fibrin: modulation by fibrinopeptide cleavage.
September 1995, Blood,
J R Shainoff, and G B Smejkal, and P M DiBello, and O V Mitkevich, and P J Levy, and C E Dempfle, and H Lill
Fibrinopeptide release from fibrinogen.
June 1983, Annals of the New York Academy of Sciences,
J R Shainoff, and G B Smejkal, and P M DiBello, and O V Mitkevich, and P J Levy, and C E Dempfle, and H Lill
The cleavage sequence of fibrinopeptide A from fibrinogen fragment E by thrombin, atroxin or batroxobin.
February 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
J R Shainoff, and G B Smejkal, and P M DiBello, and O V Mitkevich, and P J Levy, and C E Dempfle, and H Lill
Fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A in pleural effusions. High turnover of fibrinogen in pleurisy.
August 1978, Scandinavian journal of respiratory diseases,
J R Shainoff, and G B Smejkal, and P M DiBello, and O V Mitkevich, and P J Levy, and C E Dempfle, and H Lill
[In vivo behavior of soluble fibrin monomer after cleavage of fibrinopeptide A].
January 1978, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
J R Shainoff, and G B Smejkal, and P M DiBello, and O V Mitkevich, and P J Levy, and C E Dempfle, and H Lill
Reactivity of fibrinogen and fibrinopeptide A containing fibrinogen fragments with antisera to fibrinopeptide A.
March 1976, Biochemistry,
J R Shainoff, and G B Smejkal, and P M DiBello, and O V Mitkevich, and P J Levy, and C E Dempfle, and H Lill
Comparison of the sequence of fibrinopeptide A cleavage from fibrinogen fragment E by thrombin, atroxin, or batroxobin.
June 1993, Thrombosis research,
J R Shainoff, and G B Smejkal, and P M DiBello, and O V Mitkevich, and P J Levy, and C E Dempfle, and H Lill
Characterization of purified recombinant fibrinogen: partial phosphorylation of fibrinopeptide A.
January 1993, Biochemistry,
Copied contents to your clipboard!